Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Abramson Cancer Center at Penn Medicine

Status: Terminated

Conditions: Non-Hodgkin Lymphoma

Treatments: Diagnostic Test: 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)

Study type: Observational

Funder types: Other

Identifiers

NCT03065790

UPCC 54416

Details and patient eligibility

About

Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult patients, at least 18 years of age
• History of histologically confirmed NHL as assessed per medical record review.
• At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT.
• Recommended to start lenalidomide.
• Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion criteria

• Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit.
• Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
• Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.